EPO and anemia (phenotype): Although anaemia has a significant negative impact on morbidity and mortality in renal dysfunction, it remained a particularly difficult challenge in this environment due to the very high cost of erythropoietin (EPO), which has necessitated higher blood transfusion rates with attendant consequences.